Ion Beam Applications, SA Stock

Equities

IBAB

BE0003766806

Advanced Medical Equipment & Technology

Real-time Euronext Bruxelles 10:37:27 2024-04-23 am EDT 5-day change 1st Jan Change
13.4 EUR +1.67% Intraday chart for Ion Beam Applications, SA +2.29% +16.12%
Sales 2023 429M 458M Sales 2024 * 489M 522M Capitalization 384M 411M
Net income 2023 -9M -9.61M Net income 2024 * 4M 4.27M EV / Sales 2023 0.63 x
Net cash position 2023 68.46M 73.12M Net cash position 2024 * 62.79M 67.06M EV / Sales 2024 * 0.66 x
P/E ratio 2023 *
-26.4 x
P/E ratio 2024 *
94.1 x
Employees 2,000
Yield 2023 *
1.59%
Yield 2024 *
2.05%
Free-Float 65.88%
More Fundamentals * Assessed data
Dynamic Chart
Ion Beam Applications SA to Recommend Dividend for 2023 CI
Transcript : Ion Beam Applications SA, 2023 Earnings Call, Mar 21, 2024
Ion Beam Applications SA Reports Earnings Results for the Full Year Ended December 30, 2023 CI
Ion Beam Applications Books Order for Electron Beam Irradiation System MT
Ion Signs Contract to Install Be-Efficient Irradiation Solution in Germany CI
Ion Beam Applications Bags Cyclotron Order MT
Bayer Strikes Supply Deal for Actinium Isotope with Belgian JV MT
Ion Beam Applications to Buy US-based Diagnostic X-ray Measurement Company Radcal MT
Ion Beam Applications SA signed an agreement to acquire all the assets of Radcal Corporation. CI
Ion Beam Applications Sa Announces the Cyclone 70 System Installed At the Ithemba Laboratory for Accelerator Based Sciences in Cape Town CI
Ion Beam Applications to Deliver Proton Therapy System to Poland's Health Technologies MT
IBA Signs Contract for a ProteusONE Proton Therapy System to be Located at the Greater Poland Cancer Center CI
Ion Beam Applications S.A., CMI Inc. and Life Molecular Imaging Announce Japanese Approval for the Reimbursement of Amyloid-Pet Diagnostic Neuraceq in Alzheimer's Disease CI
Ion Beam Applications S.A. Announces Start of the Installation of a Cyclone 30 XP in Poland CI
Ion Beam Applications Signs Research Partnership with University of Kansas Medical Center MT
More news

Latest transcript on Ion Beam Applications, SA

1 day+0.46%
1 week+1.07%
Current month+1.07%
1 month+6.60%
3 months+27.80%
6 months+48.76%
Current year+14.73%
More quotes
1 week
12.92
Extreme 12.92
13.46
1 month
11.96
Extreme 11.96
14.00
Current year
9.31
Extreme 9.31
14.00
1 year
8.26
Extreme 8.26
17.20
3 years
8.26
Extreme 8.26
20.45
5 years
6.01
Extreme 6.01
20.45
10 years
6.01
Extreme 6.01
56.94
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 95-12-31
Founder 76 86-03-27
Director of Finance/CFO 46 03-12-31
Members of the board TitleAgeSince
Chairman 63 86-12-31
Director/Board Member 77 17-04-30
Founder 76 86-03-27
More insiders
Date Price Change Volume
24-04-23 13.4 +1.67% 13 953
24-04-22 13.18 -0.60% 14,637
24-04-19 13.26 +0.15% 19,347
24-04-18 13.24 +1.22% 32,918
24-04-17 13.08 -0.15% 59,442

Real-time Euronext Bruxelles, April 23, 2024 at 03:51 am EDT

More quotes
Ion Beam Applications, SA (IBA) specializes in the design, manufacture, and marketing of cancer treatment and diagnosis equipment. Net sales break down by family of products as follows: - diagnosis and therapeutic treatment equipment and systems (85.1%): proton therapy equipment (71.2% of net sales; No. 1 worldwide), and particle accelerators (28.8%) used in the production of radioisotopes (cyclotrons) and in the development of sterilization and ionization solutions (Rhodotron® and Dynamitron®); - equipment and solutions of dosimetry (14.9%; No. 1 worldwide): measurement and analysis tools of the radiation doses in medical imaging and radiation therapy. Net sales are distributed geographically as follows: Belgium (1.2%), the United States (35.3%) and other (63.5%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
13.18 EUR
Average target price
16.17 EUR
Spread / Average Target
+22.66%
Consensus

Quarterly revenue - Rate of surprise